|Title:||Ferric organic compounds, uses thereof and methods of making same|
|Abstract:|| The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy.|
|Inventor(s):|| Kwok; David W. K. (Vancouver, CA), Stoynov; Nikolay Mintchev (Vancouver, CA) |
|Assignee:|| Panion & BF Biotech Inc. (TW) |
1. A method of treating hyperphosphatemia, comprising: administering a therapeutically effective amount of an orally administrable form of ferric citrate to a subject,
wherein the orally administrable form is prepared from a form of ferric citrate having a BET active surface area greater than about 16 sq. m/g; and wherein the orally administrable form is selected from a tablet, a powder, a capsule, a granule, a
troche and a pill.
2. The method of claim 1, wherein the BET active surface area ranges from about 16 sq. m/g to about 20 sq. m/g.
3. The method of claim 1, wherein the ferric citrate has an intrinsic dissolution rate of at least 1.88 mg/cm.sup.2/min.
4. The method of claim 3, wherein the intrinsic dissolution rate is 1.88 to 4.0 mg/cm.sup.2/min.
5. The method of claim 3, wherein the intrinsic dissolution rate is 1.9 to 4.0 mg/cm2/min.
6. The method of claim 1, wherein the ferric citrate has the formula C.sub.6H.sub.5O.sub.7Fe.
7. The method of claim 1, wherein the orally administrable form is a tablet.
8. The method of claim 1, wherein the therapeutically effective amount is about 3 to 6 grams per day.
9. The method of claim 1, wherein the subject is a human being.